MedTrace Logo

Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

NCT00051688 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2006-07-11

No results posted yet for this study

Summary

The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

tezacitabine

DRUG

oxaliplatin

Sponsors & Collaborators

  • Chiron Corporation

    lead INDUSTRY

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2004-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00051688 on ClinicalTrials.gov